Form 8-K - Current report:
SEC Accession No. 0001420720-22-000022
Filing Date
2022-05-12
Accepted
2022-05-12 16:10:56
Documents
13
Period of Report
2022-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20220512x8k.htm   iXBRL 8-K 33101
2 EX-99.1 ibio-20220512xex99d1.htm EX-99.1 256205
  Complete submission text file 0001420720-22-000022.txt   421906

Data Files

Seq Description Document Type Size
3 EX-101.SCH ibio-20220512.xsd EX-101.SCH 2767
4 EX-101.LAB ibio-20220512_lab.xml EX-101.LAB 13524
5 EX-101.PRE ibio-20220512_pre.xml EX-101.PRE 10120
7 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20220512x8k_htm.xml XML 4575
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

EIN.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 22917901
SIC: 2834 Pharmaceutical Preparations